Joshua C. Bufton

Also affiliated with University of Bristol

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Receptor-interacting protein kinase 2 (RIPK2) and nucleotide-binding oligomerization domain (NOD) cell signaling inhibitors based on a 3,5-diphenyl-2-aminopyridine scaffold”.

Receptor-interacting protein kinase 2 (RIPK2) and nucleotide-binding oligomerization domain (NOD) cell signaling inhibitors based on a 3,5-diphenyl-2-aminopyridine scaffold

European Journal of Medicinal Chemistry(2020)10.1016/j.ejmech.2020.112417

N/A

0DataRank · unranked

20 citations

Bing Dai, Daniel M. Pinkas, Anantha Lakshmi Duddupudi, Li Li, Joshua C. Bufton +7 more

BTB domain mutations perturbing KCTD15 oligomerisation cause a distinctive frontonasal dysplasia syndrome

Journal of Medical Genetics(2024)10.1136/jmg-2023-109531

N/A

0DataRank · unranked

12 citations

David A. Cruz Walma, Daniel M. Pinkas, Rebecca S Tooze, Joshua C. Bufton, William Richardson +13 more